Related references
Note: Only part of the references are listed.Biological Utility of Fluorinated Compounds: from Materials Design to Molecular Imaging, Therapeutics and Environmental Remediation
Cheng Zhang et al.
CHEMICAL REVIEWS (2022)
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
Andreas Luttens et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication
Julien Sourimant et al.
SCIENCE (2022)
The role of antiviral treatment in the COVID-19 pandemic
Talha Khan Burki
LANCET RESPIRATORY MEDICINE (2022)
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay
Wenyue Cao et al.
ACS CENTRAL SCIENCE (2022)
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
Huahao Fan et al.
LANCET MICROBE (2022)
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CLProtease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Role of favipiravir in the treatment of COVID-19
Shashank Joshi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drozdzal et al.
DRUG RESISTANCE UPDATES (2021)
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
Steven S. Good et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
Kaho Shionoya et al.
FRONTIERS IN MICROBIOLOGY (2021)
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Malina A. Bakowski et al.
NATURE COMMUNICATIONS (2021)
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Flavio A. Cadegiani et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2021)
Tuning of the Aggregation Behavior of Fluorinated Polymeric Nanoparticles for Improved Therapeutic Efficacy
Cheng Zhang et al.
ACS NANO (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Contribution of Organofluorine Compounds to Pharmaceuticals
Munenori Inoue et al.
ACS OMEGA (2020)
Favipiravir - a Modern Antiviral Drug: Synthesis and Modifications
Yulia A. Titova et al.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2020)
Dexamethasone: A boon for critically ill COVID-19 patients?
Shailesh Kumar Patel et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
Anahita Sadeghi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
Steffen Jockusch et al.
SCIENTIFIC REPORTS (2020)
Integrating Fluorinated Polymer and Manganese-Layered Double Hydroxide Nanoparticles as pH-activated 19F MRI Agents for Specific and Sensitive Detection of Breast Cancer
Cheng Zhang et al.
SMALL (2019)
PFPE-Based Polymeric 19F MRI Agents: A New Class of Contrast Agents with Outstanding Sensitivity
Cheng Zhang et al.
MACROMOLECULES (2017)
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2016)
Fluorine in medicinal chemistry
Sophie Purser et al.
CHEMICAL SOCIETY REVIEWS (2008)